glp 1 bipolar Can GLP-1s Help People With Disorder? GLP-1 and the Degenerating Brain:

Skyrizi (risankizumab-rzaa) Disease area(s): Immunology Manufacturer(s): AbbVie 2024 Sales (USD): $11.72 billion Why it sold so well: AbbVies IL-23 inhibitor Skyrizi had remarkable growth in 2024, with global net revenues hitting $11 billion a 57.7% increase from 2023

Modulating gastric emptying, such as accelerating emptying using a prokinetic agent such as erythromycin or retarding it with morphine (10) or nutrient preloads (eg, protein) (11), has been shown to acutely increase or decrease PPG excursions, respectively, in T2D

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al

Journal of Marketing Research, 2025